We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

60 hedge funds and large institutions have $12M invested in Galectin Therapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

64% more call options, than puts

Call options by funds: $450K | Put options by funds: $275K

9% more funds holding

Funds holding: 55 → 60 (+5)

0.24% more ownership

Funds ownership: 12.35% → 12.58% (+0.24%)

6% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 16

21% less capital invested

Capital invested by funds: $15.2M → $12M (-$3.14M)

Holders
60
Holders Change
+5
Holders Change %
+9.09%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
15
Reduced
16
Closed
4
Calls
$450K
Puts
$275K
Net Calls
+$175K
Net Calls Change
-$236K

Top Buyers

Rank Fund Capital Flow
1
STA
Summit Trail Advisors
New York
+$46.2K
2
CF
Centaurus Financial
California
+$40.9K
3
Osaic Holdings
Osaic Holdings
Arizona
+$35.6K
4
Wolverine Trading
Wolverine Trading
Illinois
+$31.7K
5
State Street
State Street
Massachusetts
+$29K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$172K
2
Millennium Management
Millennium Management
New York
-$131K
3
Citadel Advisors
Citadel Advisors
Florida
-$84K
4
Morgan Stanley
Morgan Stanley
New York
-$57.7K
5
JF
Jump Financial
Illinois
-$48K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.13M -$19.1K -9,881 -0.5%
Osaic Holdings
2
Osaic Holdings
Arizona
$2.04M +$35.6K +18,419 +1%
BlackRock
3
BlackRock
New York
$1.28M +$7.15K +3,694 +0.5%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$898K -$2.88K -1,488 -0.3%
GWM
5
Geneos Wealth Management
Colorado
$764K -$11.6K -6,000 -1%
Millennium Management
6
Millennium Management
New York
$544K -$131K -67,648 -17%
AWS
7
Atria Wealth Solutions
New York
$460K +$553K +285,700 New
Renaissance Technologies
8
Renaissance Technologies
New York
$325K -$25.9K -13,382 -6%
State Street
9
State Street
Massachusetts
$280K +$29K +14,981 +9%
CCB
10
Cutter & Co Brokerage
Missouri
$273K -$26.9K -13,879 -8%
Cambridge Investment Research Advisors
11
Cambridge Investment Research Advisors
Iowa
$234K -$15.1K -7,820 -5%
KeyBank National Association
12
KeyBank National Association
Ohio
$161K – – –
Northern Trust
13
Northern Trust
Illinois
$150K -$871 -450 -0.5%
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$130K -$172K -89,095 -53%
Morgan Stanley
15
Morgan Stanley
New York
$102K -$57.7K -29,794 -32%
LPL Financial
16
LPL Financial
California
$94K +$21.1K +10,900 +23%
PNC Financial Services Group
17
PNC Financial Services Group
Pennsylvania
$90K +$19.4K +10,000 +22%
DADC
18
D.A. Davidson & Co
Montana
$89K – – –
SF
19
Synovus Financial
Georgia
$77K – – –
AAS
20
Ameritas Advisory Services
Nebraska
$71K – – –
SWP
21
Stratos Wealth Partners
Ohio
$66K – – –
MML Investors Services
22
MML Investors Services
Massachusetts
$62K +$9.68K +5,000 +15%
WS
23
Wedbush Securities
California
$45K -$3.87K -2,000 -7%
BFEC
24
Benjamin F. Edwards & Company
Missouri
$45K -$3.44K -1,779 -6%
Commonwealth Equity Services
25
Commonwealth Equity Services
Massachusetts
$43K +$19.4K +10,000 +59%
1
2 3

GALT Hedge Fund Activity: Q1 2022 in Review

60 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2022, worth a combined $12M — down 21% from $15.2M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new GALT positions and 4 closed out — a net gain of 5 holders — while 15 added to existing stakes and 16 trimmed.

The largest buyer was Summit Trail Advisors, opening a new position worth an estimated $46.2K. The largest seller was Susquehanna International Group, cutting an estimated $172K.

  • 60 institutional investors held Galectin Therapeutics (GALT) as of Q1 2022, up from 55 in Q4 2021.
  • Funds reported $12M of Galectin Therapeutics stock for Q1 2022, down 21% quarter-over-quarter.
  • 9 funds opened new Galectin Therapeutics positions in Q1 2022 and 4 closed out, a net change of +5 holders.
  • The largest Galectin Therapeutics buyer in Q1 2022 was Summit Trail Advisors, an estimated $46.2K added.
  • The largest Galectin Therapeutics seller in Q1 2022 was Susquehanna International Group, an estimated $172K sold.

Based on aggregated 13F filings for Q1 2022.